Curocell Inc. Logo

Curocell Inc.

A clinical-stage biotech developing CAR-T therapies for blood cancers.

372320 | KO

Overview

Corporate Details

ISIN(s):
KR7372320002
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학16로 11, 대전광역시

Description

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-14 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-26 00:00
정기주주총회결과
Korean 19.0 KB
2025-03-14 00:00
감사보고서제출
Korean 25.5 KB
2025-03-14 00:00
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-03-10 00:00
주주총회소집결의
Korean 8.0 KB
2025-03-10 00:00
주주총회소집공고
Korean 168.8 KB
2025-03-10 00:00
주식매수선택권부여에관한신고
Korean 17.5 KB
2025-02-21 00:00
증권발행결과(자율공시) (제2회차 CB)
Korean 5.6 KB
2025-02-19 00:00
주요사항보고서(전환사채권발행결정)
Korean 158.3 KB
2024-12-30 00:00
투자판단관련주요경영사항 (림카토주(안발셀) 한국 품목허가 신청)
Korean 11.7 KB
2024-12-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2024-12-16 00:00
주식등의대량보유상황보고서(일반)
Korean 91.2 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-12-10 00:00
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Curocell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Curocell Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Curocell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.